Loading the section…
The price of Longeveron Inc. (LGVN) on October 9, 2026 is 2.48 USD, +4.64% on the day. Over 52 weeks the stock traded between 2.30 USD and 12.30 USD; the price now sits 2% of the way up that range. Over the past year the price changed by −73.25%. Market capitalization is 4.36 million USD, rank 331 among 373 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): −69.00 %
Longeveron Inc. trades on Nasdaq under the ticker LGVN. The company belongs to the Health care sector. The trading history on this page starts on 12 February 2021.
Over the past 52 weeks LGVN has traded between 2.30 $ and 12.30 $. As of 9 October 2026 the price stood 1.80 % of the way from the 52-week low to the high.
Over one year LGVN shares fell 73.25 %; over six months they fell 78.62 %. Volatility over 90 days is 170.16 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 3.6, below the sector median of 4.0. Price to book is 0.3, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 2.40 | 2.60 | 2.34 | 2.48 | 58,400 |
| 8 October 2026 | 2.45 | 2.57 | 2.32 | 2.37 | 77,200 |
| 7 October 2026 | 2.33 | 2.48 | 2.33 | 2.44 | 58,100 |
| 6 October 2026 | 2.50 | 2.50 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Address:1951 NW 7TH AVENUE SUITE 520, MIAMI, FL, 33136, US
Longeveron Inc. reported revenue of 1M $ and a net loss of 22M $ over the last four quarters. Net margin is −1,844.49 %. Revenue changed by −45.35 % year over year. Earnings per share are −11.40 $. Market capitalisation is 4M $.
LGVN has a return on equity of −139.95 %, below the sector median of −41.68 %. Return on assets is −105.75 %, below the sector median of −32.11 %. Operating margin is −1,881.66 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 2.34 |
| 2.35 |
| 83,600 |
| 5 October 2026 | 2.59 | 2.69 | 2.51 | 2.51 | 44,200 |
| 2 October 2026 | 2.56 | 2.68 | 2.54 | 2.58 | 20,800 |
| 1 October 2026 | 2.72 | 2.74 | 2.52 | 2.59 | 72,900 |
| 30 September 2026 | 2.73 | 2.80 | 2.61 | 2.69 | 55,000 |
| 29 September 2026 | 2.68 | 2.74 | 2.60 | 2.72 | 55,200 |
| 28 September 2026 | 2.79 | 2.79 | 2.62 | 2.63 | 97,000 |
| 25 September 2026 | 2.89 | 2.95 | 2.76 | 2.81 | 50,100 |
| 24 September 2026 | 2.54 | 2.97 | 2.50 | 2.91 | 172,000 |
| 23 September 2026 | 2.68 | 2.76 | 2.53 | 2.60 | 62,300 |
| 22 September 2026 | 2.47 | 2.83 | 2.32 | 2.72 | 233,500 |
| 21 September 2026 | 2.49 | 2.54 | 2.33 | 2.45 | 171,500 |
| 18 September 2026 | 2.80 | 2.80 | 2.30 | 2.49 | 522,900 |
| 17 September 2026 | 3.23 | 3.35 | 2.70 | 2.71 | 1M |
| 16 September 2026 | 6.83 | 7.15 | 6.52 | 6.68 | 316,600 |
| 15 September 2026 | 6.89 | 7.10 | 6.65 | 6.86 | 44,200 |
| 14 September 2026 | 7.20 | 7.60 | 6.92 | 6.92 | 61,800 |